207 related articles for article (PubMed ID: 29534197)
1. Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.
Unger JM; Hershman DL; Till C; Tangen CM; Barlow WE; Ramsey SD; Goodman PJ; Thompson IM
J Natl Cancer Inst; 2018 Nov; 110(11):1208-1215. PubMed ID: 29534197
[TBL] [Abstract][Full Text] [Related]
2. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.
Unger JM; Till C; Thompson IM; Tangen CM; Goodman PJ; Wright JD; Barlow WE; Ramsey SD; Minasian LM; Hershman DL
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27565902
[TBL] [Abstract][Full Text] [Related]
3. Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors-A Large Population-Based Prospective Study.
Wallerstedt A; Strom P; Gronberg H; Nordstrom T; Eklund M
J Natl Cancer Inst; 2018 Nov; 110(11):1216-1221. PubMed ID: 29548030
[TBL] [Abstract][Full Text] [Related]
4. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
[TBL] [Abstract][Full Text] [Related]
5. Treatment with finasteride and prostate cancer survival.
Kjellman A; Friis S; Granath F; Gustafsson O; Sørensen HT; Akre O
Scand J Urol; 2013 Aug; 47(4):265-71. PubMed ID: 23137166
[TBL] [Abstract][Full Text] [Related]
6. [The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].
Schmitz-Dräger BJ; Fischer C; Bismarck E; Dörsam HJ; Lümmen G
Urologe A; 2007 Oct; 46(10):1364, 1366-8, 1370. PubMed ID: 17874228
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival of participants in the prostate cancer prevention trial.
Thompson IM; Goodman PJ; Tangen CM; Parnes HL; Minasian LM; Godley PA; Lucia MS; Ford LG
N Engl J Med; 2013 Aug; 369(7):603-10. PubMed ID: 23944298
[TBL] [Abstract][Full Text] [Related]
8. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
[TBL] [Abstract][Full Text] [Related]
9. Re: Using Medicare Claims to Examine Long-Term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.
Resnick MJ
J Urol; 2018 Oct; 200(4):689. PubMed ID: 30227567
[No Abstract] [Full Text] [Related]
10. The influence of finasteride on the development of prostate cancer.
Thompson IM; Goodman PJ; Tangen CM; Lucia MS; Miller GJ; Ford LG; Lieber MM; Cespedes RD; Atkins JN; Lippman SM; Carlin SM; Ryan A; Szczepanek CM; Crowley JJ; Coltman CA
N Engl J Med; 2003 Jul; 349(3):215-24. PubMed ID: 12824459
[TBL] [Abstract][Full Text] [Related]
11. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
Azoulay L; Eberg M; Benayoun S; Pollak M
JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
[TBL] [Abstract][Full Text] [Related]
12. Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial.
Murtola TJ; Gurel B; Umbehr M; Lucia MS; Thompson IM; Goodman PJ; Kristal AR; Parnes HL; Lippman SM; Sutcliffe S; Peskoe SB; Barber JR; Drake CG; Nelson WG; De Marzo AM; Platz EA
Cancer Epidemiol Biomarkers Prev; 2016 Mar; 25(3):463-9. PubMed ID: 26715424
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?
Lynn R; Krunic A
Dermatol Ther; 2010; 23(5):544-6. PubMed ID: 20868409
[TBL] [Abstract][Full Text] [Related]
14. PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.
Kaplan SA; Roehrborn CG; Meehan AG; Liu KS; Carides AD; Binkowitz BS; Heyden NL; Vaughan ED
Urology; 2009 May; 73(5):935-9. PubMed ID: 19328538
[TBL] [Abstract][Full Text] [Related]
15. Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study.
Yao S; Till C; Kristal AR; Goodman PJ; Hsing AW; Tangen CM; Platz EA; Stanczyk FZ; Reichardt JK; Tang L; Neuhouser ML; Santella RM; Figg WD; Price DK; Parnes HL; Lippman SM; Thompson IM; Ambrosone CB; Hoque A
Cancer Causes Control; 2011 Aug; 22(8):1121-31. PubMed ID: 21667068
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.
Etzioni RD; Howlader N; Shaw PA; Ankerst DP; Penson DF; Goodman PJ; Thompson IM
J Urol; 2005 Sep; 174(3):877-81. PubMed ID: 16093979
[TBL] [Abstract][Full Text] [Related]
17. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
Reed AB; Parekh DJ
Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950
[TBL] [Abstract][Full Text] [Related]
18. Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.
Winchester DA; Till C; Goodman PJ; Tangen CM; Santella RM; Johnson-Pais TL; Leach RJ; Xu J; Zheng SL; Thompson IM; Lucia MS; Lippman SM; Parnes HL; Isaacs WB; De Marzo AM; Drake CG; Platz EA
Prostate; 2017 Jun; 77(8):908-919. PubMed ID: 28317149
[TBL] [Abstract][Full Text] [Related]
19. Circadian genes and risk of prostate cancer in the prostate cancer prevention trial.
Chu LW; Till C; Yang B; Tangen CM; Goodman PJ; Yu K; Zhu Y; Han S; Hoque AM; Ambrosone C; Thompson I; Leach R; Hsing AW
Mol Carcinog; 2018 Mar; 57(3):462-466. PubMed ID: 29318656
[TBL] [Abstract][Full Text] [Related]
20. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.
Redman MW; Tangen CM; Goodman PJ; Lucia MS; Coltman CA; Thompson IM
Cancer Prev Res (Phila); 2008 Aug; 1(3):174-81. PubMed ID: 19138953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
